Jagdish Butany, MBBS, MS, FRCPC, Department of Pathology, Toronto General Hospital, University Health Network; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto ...

BACKGROUND: Classically, hypertrophic cardiomyopathy (HCM) has been viewed as a single-gene (monogenic) disease caused by ...

Opens in a new tab or window A small panel of circulating biomarkers may reliably distinguish hypertrophic cardiomyopathy (HCM) from similar conditions that cause left ventricular hypertrophy (LVH ...

Hypertrophic cardiomyopathy is an inherited condition that affects up to 750,000 people in the United States. It often ...

Opens in a new tab or window CHICAGO -- Gene therapy for Danon disease, a rare inherited cause of hypertrophic cardiomyopathy, appeared to improve or stabilize the structure and function of the ...

Favorable short- and long-term outcomes are seen in patients with hypertrophic cardiomyopathy who receive septal reduction therapy.

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular condition. It is the leading cause of sudden ...

Aim Differentiating physiological cardiac hypertrophy from pathology is challenging when the athlete ... Three athletes were diagnosed with a cardiomyopathy (0.4% prevalence); with two athletes ...

The FDA has accepted for review the New Drug Application for aficamten for the treatment of obstructive hypertrophic cardiomyopathy.

claiming a green light from the US regulator for mavacamten as a therapy for obstructive hypertrophic cardiomyopathy (HCM). Orally-active mavacamten – which was acquired by BMS when it bought ...

Hypertrophic cardiomyopathy (HCM) is a rare condition that occurs when your heart muscle becomes abnormally thick. This ...